Placebo plus Docetaxel

DRUG4 trials

Sponsors

Boehringer Ingelheim, Simcere Pharmaceutical Co., Ltd, Infinity Pharmaceuticals, Inc., Jiangsu HengRui Medicine Co., Ltd.

Conditions

Advanced NSCLCCarcinoma, Non-Small-Cell LungNon Small Cell Lung CancerNon Squamous Non Small Cell LungRecurrent NSCLC

Phase 2

A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer

CompletedNCT01362400

Infinity Pharmaceuticals, Inc.Non Small Cell Lung Cancer

Start: 2011-05-31End: 2014-04-30Updated: 2014-05-19

Phase 3

LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer

CompletedNCT00805194

Boehringer IngelheimCarcinoma, Non-Small-Cell Lung

Start: 2008-12-03End: 2017-11-13Updated: 2018-12-05

SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung Cancer

TerminatedNCT02766140

Jiangsu HengRui Medicine Co., Ltd.Non Squamous Non Small Cell Lung

Start: 2016-06-30End: 2016-11-30Updated: 2019-01-18

Phase 4

Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NSCLC)

Simcere Pharmaceutical Co., LtdAdvanced NSCLC, Recurrent NSCLC

Start: 2008-10-31End: 2010-10-31Target: 300Updated: 2010-01-25

Related Papers

Anlotinib in combination with docetaxel for advanced nonsmall cell lung cancer after failure of platinum‐based treatment: A phase 1/2 trial

Cancer2025-05-141 citations

Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study.

2017-08-0121 citations

Nintedanib, a novel triple angiokinase inhibitor for the treatment of non-small cell lung cancer.

2015-06-015 citations

Tumor growth over time in patients with non-small cell lung cancer (NSCLC) of adenocarcinoma histology (ACH) treated with nintedanib and docetaxel or placebo and docetaxel: Analysis of data from the LUME-Lung 1 (LL1) study.

Journal of Clinical Oncology2015-05-202 citations

Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer.

2014-12-1749 citations

Antiangiogenic-specific adverse events (AEs) in patients with non-small cell lung cancer (NSCLC) treated with nintedanib (N) and docetaxel (D).

Journal of Clinical Oncology2014-05-204 citations

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.

2014-01-09721 citations

Nintedanib Plus Docetaxel Improves PFS and OS for Patients with Stage IIIB/IV or Recurrent Lung Adenocarcinoma

MD Conference Express2013-07-01

Nintedanib (BIBF 1120) plus docetaxel in NSCLC patients progressing after first-line chemotherapy: LUME Lung 1, a randomized, double-blind phase III trial.

Journal of Clinical Oncology2013-06-2032 citations